The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...
(RTTNews) - Assembly Biosciences (ASMB), a biotechnology company focused on developing treatments for viral diseases, announced on Wednesday that the first participant has been dosed in its Phase 1a ...
At its second attempt, Gilead Sciences has won FDA approval for chronic hepatitis D virus (HDV) therapy Hepcludex, almost four years after it got the go-ahead in Europe. The accelerated approval makes ...
Researchers from Assembly Biosciences Inc. recently presented details on the discovery and preclinical evaluation of a novel small-molecule hepatitis B virus (HBV) and hepatitis D virus (HDV) entry ...
Assembly Biosciences Inc. has selected ABI-6250, an orally bioavailable small-molecule entry inhibitor, as a development candidate to progress to IND-enabling studies for the treatment of chronic ...
– Late-breaker poster highlights preclinical profile of ABI-6250, currently in Phase 1a with data anticipated in Q3 2025 – – Second poster describes in vitro studies of effects on viral infection ...
The last time I spoke about Assembly Biosciences (ASMB) it was in a Seeking Alpha article entitled "Assembly Biosciences: Positive Data Of ABI-5366 Brings 2 Fall Program Catalysts." With respect to ...
SOUTH SAN FRANCISCO, Calif., May 13, 2026 (GLOBE NEWSWIRE) -- Assembly Biosciences, Inc. (Nasdaq: ASMB), a biotechnology company developing innovative therapeutics targeting serious viral diseases, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results